Compass Launches Compass One: The Industry’s First-Ever All-in-One Client Dashboard Connecting Compass Agents to Their Clients In Real Time

PR Newswire

Compass Provides Agents with a Platform to Guide Buyers and Sellers Through Every Step of Their Homeownership Journey


NEW YORK
, Feb. 3, 2025 /PRNewswire/ — Compass (NYSE: COMP), the largest residential real estate brokerage in the United States by sales volume1, announces the launch of Compass One, the client-facing version of its end-to-end technology platform for real estate agents. Compass One is the only platform designed to connect you and your agent through every phase of your real estate journey and experience 24/7 transparency before, during, and after the transaction for total peace of mind. Through Compass One, agents invite their clients to an all-in-one experience where they can access the tools, services, and advantages Compass offers. Compass One will help strengthen agent-client relationships, drive repeat and referral business, and unlock new opportunities for ancillary services.

“Compass has invested $1.6 billion to create the industry’s leading technology platform for real estate agents,” said Ori Allon, Compass Founder. “With Compass One, we’re bringing that same innovation to consumers, offering a single access point that seamlessly connects them with their agent through their real estate journey.”

“Buying and selling a home can be stressful and confusing—but it doesn’t have to be,” said Compass Founder and CEO Robert Reffkin. “By enabling agents with technology that delivers 24/7 transparency before, during, and after the transaction, Compass One showcases the agent’s value well beyond just facilitating transactions: It reinforces their role as trusted, full-service real estate advisors, providing clients with expert guidance at every stage of homeownership.”

Home buying and selling can often feel overwhelming and complex, with limited visibility at each stage of the transaction. Compass One aims to eliminate these challenges by providing a streamlined, stress-free experience that guides consumers through every phase of their homeowner journey—before, during, and after their real estate transaction:

  • Before the transaction: Compass agents invite their clients to the platform, where they gain access to a curated dashboard and customized timeline. Buyers can easily review their home search collection, view their home tour, review personalized market analyses, and access Compass-exclusive inventory. Sellers gain access to a custom market valuation of their home, real-time visibility into neighborhood trends, and powerful pre-marketing tools like Compass’ 3-Phased Marketing Strategy.
  • During the transaction: Compass One becomes the single access point to keep clients informed once the home is in contract. Agents can share upcoming steps, key dates, tasks for clients to complete, and essential documents, ensuring clients stay organized and informed.
  • After the transaction: Compass One offers an easy way for clients to access documentation and stay connected with their agents, who can provide regular market updates and guidance on homeownership or future real estate needs.

Compass One was developed by Compass’ in-house technology team — the largest in the brokerage industry — and combines high-tech solutions with high-touch service, empowering agents with best-in-class tools and support to grow their business, streamline transactions, and deliver exceptional client experiences.

For more information, visit: https://one.compass.com/

About Compass

Compass is the largest residential real estate brokerage in the United States by sales volume. Founded in 2012 and based in New York City, Compass provides an end-to-end platform that empowers its residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service, brokerage services, settlement services, and other critical functionality, all custom-built for the real estate industry. Compass agents utilize the platform to grow their business, save time, and manage it more effectively. The Compass network includes Christie’s International Real Estate, the world’s premier global luxury real estate brand with over 100 independently owned brokerage Affiliates in 50 countries and territories. For more information on how Compass empowers real estate agents, one of the country’s largest groups of small business owners, please visit www.compass.com.


1
 Compass was ranked number one real estate brokerage in sales volume for 2023 by Real Trends in March 2024 for the third year in a row

CONTACT:
Devin Daly Huerta
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/compass-launches-compass-one-the-industrys-first-ever-all-in-one-client-dashboard-connecting-compass-agents-to-their-clients-in-real-time-302366747.html

SOURCE COMPASS

CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PR Newswire


LA JOLLA, Calif.
, Feb. 3, 2025 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12, 2025, at 8:00 a.m. ET.

A live webcast of the presentation can be accessed in the “Upcoming Events” section of CalciMedica’s IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company’s website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica’s proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected in 2025 and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with data expected in 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.

Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
[email protected] 
(212) 600-1902

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-oppenheimer-35th-annual-healthcare-life-sciences-conference-302366737.html

SOURCE CalciMedica, Inc.

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire


NEWTON, Mass.
, Feb. 3, 2025 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 28,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted as of January 31, 2025 (the “Grant Date”) pursuant to the Company’s 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee’s continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

In addition, each RSU award will be immediately exercisable in full if, on or prior to the first anniversary of the consummation of a “change in control event,” the employee’s employment is terminated for “good reason” by the employee or terminated without “cause” by Karyopharm (as such terms are defined in the 2022 Inducement Stock Incentive Plan, as amended).

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm’s lead compound and first­in­class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in a growing number of ex­U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302363681.html

SOURCE Karyopharm Therapeutics Inc.

Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, today announced that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.

Format: Company Presentation and 1×1 Investor Meetings

Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor of MEK designed to improve tolerability and expand indications to include RAS-driven tumors such as most pancreatic cancers. IMM-1-104 is currently in a Phase 1/2a trial in patients with advanced solid tumors including pancreatic cancer. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor of MEK currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:

Gina Nugent
[email protected]

Investor Contact:

Laurence Watts
619-916-7620
[email protected]



NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th

MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.

Presentation Details:
Title: Multicenter Post-approval Study of the RNS System in Focal Epilepsy
Presenter: Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of the UCLA Seizure Disorders Center
Session: S20: Epilepsy Clinical Outcomes and Prognostication
Presentation number: 009
Date and Time: Monday, April 7th, at 5:06 PM PT
   

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Investor Contact:

Jeremy Feffer
Managing Director
LifeSci Advisors
[email protected]



SeaStar Medical Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market

DENVER, Feb. 03, 2025 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rule, with a single institutional investor for the issuance and sale of an aggregate of 3,529,412 shares of its common stock (or pre-funded warrants in lieu thereof). In a concurrent private placement, the Company issued and sold to the investor warrants to purchase up to an aggregate of 3,529,412 shares common stock.

The combined offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants was $1.70 (or $1.699 with respect to pre-funded warrants). The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance, and will not expire until fully exercised. The warrants have an exercise price of $1.70 per share, are exercisable upon shareholder approval and will expire five years following the shareholder approval date.

The gross proceeds from the offering were approximately $6 million. SeaStar Medical intends to use the net proceeds of this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

H.C. Wainwright & Co. is the exclusive investment bank for the Company.

The shares of common stock, pre-funded warrants, and shares of common stock underlying the pre-funded warrants were offered by SeaStar Medical pursuant to a shelf registration statement on Form S-3 (File No. 333-275968) that was previously filed with the Securities and Exchange Commission (“SEC”) on December 8, 2023, and subsequently declared effective on December 22, 2023. The securities offered in the registered direct offering have been offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying base prospectus relating to, and describing the terms of, the registered direct offering have been filed with the SEC and is available on the SEC’s website at www.sec.gov.

The warrants issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About SeaStar Medical

SeaStar Medical is a commercial-stage therapeutic medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, statements related to the use of proceeds from the offering and SeaStar Medical’s ability to receive shareholder approval. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, (ix) market and other conditions; and (x) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

Alliance Advisors IR
Jody Cain
(310) 691-7100
[email protected]

# # #



Highwoods Announces Recent Investment and Financing Activity

RALEIGH, N.C., Feb. 03, 2025 (GLOBE NEWSWIRE) — Highwoods Properties, Inc. (NYSE:HIW) is today announcing investment and financing transactions that closed during the fourth quarter of 2024 and to date in early 2025.

First, the Company has sold in a series of transactions non-core buildings in Raleigh and Tampa for combined gross proceeds of $166.4 million. Gross proceeds from dispositions closed in the fourth quarter of 2024 totaled $21.4 million with the remainder closing early in the first quarter of 2025. The sold properties include one office building encompassing 170,000 square feet in North Raleigh and three buildings encompassing 616,000 square feet in the Westshore submarket of Tampa. On a combined basis, these properties are 88% occupied and were projected to generate $13.6 million of GAAP net operating income and $13.0 million of cash net operating income in 2025.

Second, in the fourth quarter of 2024, the Company acquired fee simple title to the land underneath its Century Center assets for $50.6 million. The Company previously held most of its buildings in Century Center, a 12-building office park encompassing 1.7 million square feet and 13 acres of developable land in the Chamblee/N. Druid Hills submarket of Atlanta, pursuant to a long-term ground lease with a third party who owned fee simple title to the land.

Third, in the fourth quarter of 2024, the Company sold 1.59 million shares of its common stock at an average gross sales price of $32.71 per share, raising net proceeds of $51.3 million.

Ted Klinck, President and Chief Executive Officer, stated, “Our recent disposition activity demonstrates our continuing ability to execute on our long-standing strategy of selling non-core assets with limited future upside and ultimately using the proceeds to recycle into higher-quality buildings. The nearly $220 million of proceeds from these non-core dispositions and equity raised during the fourth quarter, further bolsters our already strong balance sheet and creates dry powder for future external growth opportunities in 2025.”

“Acquiring the land underneath our Century Center assets consolidates our ownership of the buildings and the land, which provides us with more long-term flexibility and certainty,” added Mr. Klinck.

About Highwoods
Highwoods Properties, Inc., headquartered in Raleigh, is a publicly-traded (NYSE:HIW), fully-integrated office real estate investment trust (“REIT”) that owns, develops, acquires, leases and manages properties primarily in the best business districts (BBDs) of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond and Tampa. Highwoods is in the work-placemaking business. We believe that by creating environments and experiences where the best and brightest can achieve together what they cannot apart, we can deliver greater value to our customers, their teammates and, in turn, our stakeholders. For more information about Highwoods, please visit our website at www.highwoods.com.

Forward-Looking Statements
Some of the information in this press release may contain forward-looking statements. Such statements include, in particular, statements about our plans, strategies and prospects such as the following: the expected financial and operational results and the related assumptions underlying our expected results; the planned sales of non-core assets and expected pricing and impact with respect to such sales, including the tax impact of such sales; the anticipated total investment, projected leasing activity, estimated replacement cost and expected net operating income of acquired properties and properties to be developed; and expected future leverage of the Company. You can identify forward-looking statements by our use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue” or other similar words. Although we believe that our plans, intentions and expectations reflected in or suggested by such forward-looking statements are reasonable, we cannot assure you that our plans, intentions or expectations will be achieved.

Factors that could cause our actual results to differ materially from Highwoods’ current expectations include, among others, the following: the financial condition of our customers could deteriorate; our assumptions regarding potential losses related to customer financial difficulties could prove incorrect; counterparties under our debt instruments, particularly our revolving credit facility, may attempt to avoid their obligations thereunder, which, if successful, would reduce our available liquidity; we may not be able to lease or re-lease second generation space, defined as previously occupied space that becomes available for lease, quickly or on as favorable terms as old leases; we may not be able to lease newly constructed buildings as quickly or on as favorable terms as originally anticipated; we may not be able to complete development, acquisition, reinvestment, disposition or joint venture projects as quickly or on as favorable terms as anticipated; development activity in our existing markets could result in an excessive supply relative to customer demand; our markets may suffer declines in economic and/or office employment growth; unanticipated increases in interest rates could increase our debt service costs; unanticipated increases in operating expenses could negatively impact our operating results; natural disasters and climate change could have an adverse impact on our cash flow and operating results; we may not be able to meet our liquidity requirements or obtain capital on favorable terms to fund our working capital needs and growth initiatives or repay or refinance outstanding debt upon maturity; and the Company could lose key executive officers.

This list of risks and uncertainties, however, is not intended to be exhaustive. You should also review the other cautionary statements we make in “Risk Factors” set forth in our 2023 Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on forward-looking statements. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements to reflect any future events or circumstances or to reflect the occurrence of unanticipated events.

Contact:        
Brendan Maiorana                                  
Executive Vice President and Chief Financial Officer        
[email protected]
919-872-4924



Solaris Energy Infrastructure Schedules Fourth Quarter and Full Year 2024 Results Conference Call

Solaris Energy Infrastructure Schedules Fourth Quarter and Full Year 2024 Results Conference Call

HOUSTON–(BUSINESS WIRE)–
Solaris Energy Infrastructure, Inc. (NYSE:SEI) (“Solaris” or the “Company”) announced today that it will host a conference call to discuss its fourth quarter and full year 2024 results on Friday, February 21, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time). Solaris will issue its fourth quarter and full year 2024 earnings release after the market closes on February 20, 2025.

Participants can join the fourth quarter and full year 2024 conference call from within the United States by dialing (844) 413-3978, or from outside of the United States by dialing (412) 317-6594, and referencing Solaris Energy Infrastructure, Inc. To listen via live webcast, please visit the Investor Relations section of the Company’s website, solaris-energy.com.

An audio replay of the conference call will be available shortly after the conclusion of the call and will remain available for approximately seven days. It can be accessed by dialing (877) 344-7529 within the United States or (412) 317-0088 outside of the United States. The conference call replay access code is 3610985. The replay will also be available in the Investor Relations section of the Company’s website shortly after the conclusion of the call and will remain available for approximately seven days.

About Solaris Energy Infrastructure, Inc.

Solaris Energy Infrastructure, Inc. (NYSE:SEI) provides mobile and scalable equipment-based solutions for use in distributed power generation as well as the management of raw materials used in the completion of oil and natural gas wells. Headquartered in Houston, Texas, Solaris serves multiple U.S. end markets, including energy, data centers, and other commercial and industrial sectors. For more details, visit solaris-energy.com.

Yvonne Fletcher

Senior Vice President, Finance and Investor Relations

(281) 501-3070

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Oil/Gas Energy

MEDIA:

Logo
Logo

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received stock options to purchase an aggregate of 34,320 shares of the company’s common stock and an aggregate of 48,540 restricted stock units (RSUs). The options have an exercise price of $7.61 per share, which is equal to the closing price of the company’s common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee’s continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first three anniversaries of April 1, 2025, subject to each such employee’s continued service with the company on each such vesting date.

About Verve Therapeutics 

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: LDL-C, remnant cholesterol, and Lp(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.

Investor Contact

Jen Robinson
Verve Therapeutics, Inc.
[email protected]

Media Contact

Ashlea Kosikowski
1AB
[email protected]



Palantir Reports Q4 2024 Revenue Growth of 36% Y/Y, U.S. Revenue Growth of 52% Y/Y; Issues FY 2025 Revenue Guidance of 31% Y/Y Growth, Eviscerating Consensus Estimates

Palantir Reports Q4 2024 Revenue Growth of 36% Y/Y, U.S. Revenue Growth of 52% Y/Y; Issues FY 2025 Revenue Guidance of 31% Y/Y Growth, Eviscerating Consensus Estimates

DENVER–(BUSINESS WIRE)–
Palantir Technologies Inc. (NASDAQ:PLTR) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024.

“Our business results continue to astound, demonstrating our deepening position at the center of the AI revolution. Our early insights surrounding the commoditization of large language models have evolved from theory to fact,” said Alexander C. Karp, Co-Founder and Chief Executive Officer of Palantir Technologies Inc. “I would also like to congratulate Palantirians for their extraordinary contributions to our growth. They have earned every bit of the compensation from the delivery of their market-vesting stock appreciation rights (SARs).”

Q4 2024 Highlights

  • U.S. revenue grew 52% year-over-year and 12% quarter-over-quarter to $558 million

    • U.S. commercial revenue grew 64% year-over-year and 20% quarter-over-quarter to $214 million

    • U.S. government revenue grew 45% year-over-year and 7% quarter-over-quarter to $343 million

  • Revenue grew 36% year-over-year and 14% quarter-over-quarter to $828 million

  • Closed 129 deals of at least $1 million, 58 deals of at least $5 million, and 32 deals of at least $10 million

  • Closed a record-setting $803 million of U.S. commercial total contract value (“TCV”), up 134% year-over-year and 170% quarter-over-quarter

  • U.S. commercial remaining deal value (“RDV”) of $1.79 billion, up 99% year-over-year and 47% quarter-over-quarter

  • Customer count grew 43% year-over-year and 13% quarter-over-quarter

  • Cash from operations of $460 million, representing a 56% margin

  • Adjusted free cash flow of $517 million, representing a 63% margin

  • GAAP net income of $79 million, representing a 10% margin

    • $165 million of net income when excluding one-time SAR-related expenses, representing a 20% margin

  • GAAP income from operations of $11 million, representing a 1% margin

    • $142 million of income from operations when excluding one-time SAR-related expenses, representing a 17% margin

  • Adjusted income from operations of $373 million, representing a 45% margin

  • Rule of 40 score of 81%

  • GAAP earnings per share (“EPS”) of $0.03

    • $0.07 EPS when excluding one-time SAR-related expenses

  • Adjusted EPS of $0.14

  • Cash, cash equivalents, and short-term U.S. Treasury securities of $5.2 billion

FY 2024 Highlights

  • U.S. revenue grew 38% year-over-year to $1.90 billion

    • U.S. commercial revenue grew 54% year-over-year to $702 million

    • U.S. government revenue grew 30% year-over-year to $1.20 billion

  • Revenue grew 29% year-over-year to $2.87 billion

  • Cash from operations of $1.15 billion, representing a 40% margin

  • Adjusted free cash flow of $1.25 billion, representing a 44% margin

  • GAAP net income of $462 million, representing a 16% margin

  • GAAP income from operations of $310 million, representing an 11% margin

    • $442 million of income from operations when excluding one-time SAR-related expenses, representing a 15% margin

  • Adjusted income from operations of $1.13 billion, representing a 39% margin

Q4 and FY 2024 Financial Summary

(Unaudited)

 

(Amounts in thousands, except percentages and per share amounts)

Fourth Quarter

 

Full Year 2024

Amount

 

Amount

Revenue

 

 

$

827,519

 

 

 

 

$

2,865,507

 

Year-over-year growth

 

 

 

36

%

 

 

 

 

29

%

 

 

 

 

 

 

 

 

 

Amount

 

Margin

 

Amount

 

Margin

Income from Operations

$

11,043

 

 

1

%

 

$

310,403

 

 

11

%

Adjusted Income from Operations

$

372,522

 

 

 

45

%

 

$

1,128,062

 

 

 

39

%

Cash from Operations

$

460,327

 

 

 

56

%

 

$

1,153,865

 

 

 

40

%

Adjusted Free Cash Flow

$

517,385

 

 

 

63

%

 

$

1,249,222

 

 

 

44

%

Net Income Attributable to Common Stockholders

$

79,009

 

 

 

10

%

 

$

462,190

 

 

 

16

%

Adjusted Net Income Attributable to Common Stockholders

$

341,947

 

 

 

 

$

1,001,849

 

 

 

Adjusted EBITDA

$

379,528

 

 

 

46

%

 

$

1,159,649

 

 

 

40

%

GAAP EPS, Diluted

$

0.03

 

 

 

 

$

0.19

 

 

 

Adjusted EPS, Diluted

$

0.14

 

 

 

 

$

0.41

 

 

 

Outlook

For Q1 2025, we expect:

  • Revenue of between $858 – $862 million.

  • Adjusted income from operations of between $354 – $358 million.

For full year 2025, we expect:

  • Revenue of between $3.741 – $3.757 billion.

  • U.S. commercial revenue in excess of $1.079 billion, representing a growth rate of at least 54%.

  • Adjusted income from operations of between $1.551 – $1.567 billion.

  • Adjusted free cash flow of between $1.5 – $1.7 billion.

  • GAAP operating income and net income in each quarter of this year.

CEO Letter

Palantir CEO Alex Karp’s annual letter is available through Palantir’s website at https://www.palantir.com/newsroom/letters.

Earnings Webcast

A live public webcast will be held at 3:00 PM MT / 5:00 PM ET today to discuss the results for our fourth quarter and year ended December 31, 2024 and financial outlook. The webcast can be accessed by registering online at https://palantir.events/palantirearnings-q42024. A replay of the webcast will be available at https://investors.palantir.com following the event.

An investor presentation, including supplemental financial information and reconciliations of certain non-GAAP measures to their nearest comparable GAAP measures, will be available through Palantir’s Investor Relations website at https://investors.palantir.com.

Forward-Looking Statements

This press release and statements on our earnings webcast contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our financial outlook, product development and related timing, distribution, and pricing, expected benefits of and applications for our software platforms, business strategy and plans (including strategy and plans relating to our Artificial Intelligence Platform (“AIP”), sales and marketing efforts, sales force, partnerships, and customers), investments in our business, market trends and market size, opportunities (including growth opportunities), our expectations regarding our existing and potential investments in, and commercial contracts with, various entities, our expectations regarding macroeconomic events, our expectations regarding our share repurchase program, and positioning. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts, and projections as well as the beliefs and assumptions of management. Words such as “guidance,” “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “plan,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall,” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to risks detailed in our filings with the Securities and Exchange Commission (the “SEC”), including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and other filings and reports that we may file from time to time with the SEC, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. In particular, the following factors, among others, could cause our results to differ materially from those expressed or implied by such forward-looking statements: our ability to successfully execute our business and growth strategy; the sufficiency of our available funds to meet our liquidity needs; the demand for our platforms, product offerings, and services in general; our ability to increase our number of new customers and revenue generated from customers; our ability to realize some or all of the total contract value of customer contracts as revenue, including any contractual options available to customers or contractual periods that are subject to termination for convenience provisions; our long and unpredictable sales cycle; our ability to successfully execute our channel sales and other strategic initiatives with third parties; our ability to retain and expand our customer base; the fluctuation of our results of operations and our key business measures on a quarterly basis in future periods; the seasonality of our business; the implementation process for our platforms, which may be complex and lengthy; our ability to successfully develop and deploy new technologies to address the needs of our existing or prospective customers; our ability to make our platforms and product offerings easier to install, consume, and use; our ability to maintain and enhance our brand and reputation; our ability to maintain and enhance our culture as our business grows and as we pursue our business and financial goals; news or social media coverage about us or our leadership, including but not limited to coverage that presents, or relies on, inaccurate, misleading, incomplete, or otherwise damaging information; the impact of recent or future global macroeconomic and geopolitical events, such as the Russia-Ukraine and Israel conflicts, heightened interest rates, monetary policy changes, or foreign currency fluctuations, on the business and operations of our company or of our existing or prospective customers and partners; issues raised by the use of artificial intelligence in our platforms; and any breach or access to our or customer or third-party data.

The forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments will cause our views to change. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Past performance is not necessarily indicative of future results.

Additional Definitions

For the purpose of this press release, our earnings webcast, and our CEO’s letter:

  • Total contract value (“TCV”) is the total potential lifetime value of contracts entered into with, or awarded by, our customers at the time of contract execution, annual contract value (“ACV”) is defined as the total value of contracts closed in the period divided by the dollar-weighted average contract duration of those same contracts, and remaining deal value (“RDV”) is the total remaining value of contracts as of the end of the reporting period. Except as noted below, TCV, ACV, and RDV each presume the exercise of all contract options available to our customers and no termination of contracts. However, the majority of our contracts are subject to termination provisions, including for convenience, and there can be no guarantee that contracts are not terminated or that contract options will be exercised. Further, RDV may exclude all or some portion of the value of certain commercial contracts as a result of our ongoing assessments of customers’ financial condition, including the consideration of such customers’ ability and intention to pay, and whether such contracts continue to meet the criteria for revenue recognition, among other factors.

  • Remaining performance obligations (“RPO”) reflect the total values of contracts that have been entered into with, or awarded by, our customers, and represent non-cancelable contracted revenue that has not yet been recognized, which includes deferred revenue and, in certain instances, amounts that will be invoiced. We have elected the practical expedient, as permitted under Accounting Standards Codification 606—Revenue from Contracts with Customers, to not disclose remaining performance obligations for contracts with original terms of twelve months or less.

  • The term “strategic commercial contracts” is as defined in our quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024.

  • “Dollar-weighted duration basis” is the total value of contracts closed in the applicable period, divided by the dollar-weighted average contract duration of those same contracts.

  • The term “Rule of 40” refers to the sum of our revenue growth rate year-over-year and our adjusted operating margin for each of the periods presented.

Non-GAAP Financial Measures

This press release and the accompanying tables, as well as our earnings webcast, and our CEO’s letter, contain the non-GAAP financial measures adjusted income from operations, which excludes stock-based compensation and related employer payroll taxes; adjusted operating margin; income from operations when excluding one-time SAR-related expenses, which excludes the one-time accelerated stock-based compensation expense and employer payroll taxes related to our Market-Vesting SARs; operating margin when excluding one-time SAR-related expenses; adjusted free cash flow; adjusted free cash flow margin; adjusted earnings before interest, taxes, depreciation, and amortization (“adjusted EBITDA”); adjusted EBITDA margin; adjusted net income attributable to common stockholders; net income when excluding one-time SAR-related expenses, which excludes the one-time accelerated stock-based compensation expense, employer payroll taxes, and income tax effects and adjustments related to our Market-Vesting SARs; EPS when excluding one-time SAR-related expenses, diluted; and adjusted EPS, diluted. Market-Vesting SARs are discussed further in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024.

We believe these non-GAAP financial measures and other metrics described in this press release help us evaluate our business, identify trends affecting Palantir’s business, formulate business plans and financial projections, and make strategic decisions. We exclude stock-based compensation, which is a non-cash expense, from these non-GAAP financial measures because we believe that excluding this item provides meaningful supplemental information regarding operational performance and provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team. We exclude employer payroll taxes related to stock-based compensation as it is difficult to predict and outside of Palantir’s control. During the year and quarter ended December 31, 2024, we also excluded the one-time accelerated stock-based compensation expense and employer payroll taxes related to our Market-Vesting SARs as each is associated with the early acceleration of such Market-Vesting SARs upon achievement of the market condition of such awards. At the time of grant, the achievement of the market condition of the Market-Vesting SARs was difficult to predict and dependent on future events that were uncertain and were not within our control. We believe separate presentation of SARs-adjusted income from operations provides useful information regarding the impacts of our Market-Vesting SARs.

Our definitions may differ from the definitions used by other companies and therefore comparability may be limited. In addition, other companies may not publish these or similar metrics. Further, these metrics have certain limitations as they do not include the impact of certain expenses that are reflected in our consolidated statements of operations. For example, adjusted free cash flow does not reflect our future contractual commitments or the total increase or decrease in our cash balances for a given period. Thus, our non-GAAP financial measures should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP.

We compensate for these limitations by providing a reconciliation of each of these non-GAAP measures to the most comparable GAAP measure. We encourage investors and others to review our business, results of operations, and financial information in their entirety, not to rely on any single financial measure, and to view these non-GAAP measures in conjunction with the most directly comparable GAAP financial measure.

A reconciliation table of the most comparable GAAP financial measure to each non-GAAP financial measure used in this press release is included at the end of this release. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, reconciling items that may be incurred in the future, such as stock-based compensation and related employer payroll taxes, the effect of which may be significant.

Available Information

Palantir uses its Investor Relations website at https://investors.palantir.com as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Palantir’s Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, and webcasts.

About Palantir Technologies Inc.

Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.

Palantir Technologies Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(unaudited)

 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Revenue

$

827,519

 

 

$

608,350

 

 

$

2,865,507

 

 

$

2,225,012

 

Cost of revenue (1)

 

174,533

 

 

 

108,639

 

 

 

565,990

 

 

 

431,105

 

Gross profit

 

652,986

 

 

 

499,711

 

 

 

2,299,517

 

 

 

1,793,907

 

Operating expenses:

 

 

 

 

 

 

 

Sales and marketing (1)

 

288,295

 

 

 

197,363

 

 

 

887,755

 

 

 

744,992

 

Research and development (1)

 

171,502

 

 

 

109,283

 

 

 

507,878

 

 

 

404,624

 

General and administrative (1)

 

182,146

 

 

 

127,271

 

 

 

593,481

 

 

 

524,325

 

Total operating expenses

 

641,943

 

 

 

433,917

 

 

 

1,989,114

 

 

 

1,673,941

 

Income from operations

 

11,043

 

 

 

65,794

 

 

 

310,403

 

 

 

119,966

 

Interest income

 

54,727

 

 

 

44,545

 

 

 

196,792

 

 

 

132,572

 

Other income (expense), net

 

14,768

 

 

 

(4,092

)

 

 

(18,022

)

 

 

(15,447

)

Income before provision for income taxes

 

80,538

 

 

 

106,247

 

 

 

489,173

 

 

 

237,091

 

Provision for income taxes

 

3,602

 

 

 

9,334

 

 

 

21,255

 

 

 

19,716

 

Net income

$

76,936

 

 

$

96,913

 

 

$

467,918

 

 

$

217,375

 

Less: Net income (loss) attributable to noncontrolling interests

 

(2,073

)

 

 

3,522

 

 

 

5,728

 

 

 

7,550

 

Net income attributable to common stockholders

$

79,009

 

 

$

93,391

 

 

$

462,190

 

 

$

209,825

 

Earnings per share attributable to common stockholders, basic

$

0.03

 

 

$

0.04

 

 

$

0.21

 

 

$

0.10

 

Earnings per share attributable to common stockholders, diluted

$

0.03

 

 

$

0.04

 

 

$

0.19

 

 

$

0.09

 

Weighted-average shares of common stock outstanding used in computing earnings per share attributable to common stockholders, basic

 

2,304,883

 

 

 

2,187,214

 

 

 

2,250,163

 

 

 

2,147,446

 

Weighted-average shares of common stock outstanding used in computing earnings per share attributable to common stockholders, diluted

 

2,528,279

 

 

 

2,357,742

 

 

 

2,450,818

 

 

 

2,297,927

 

 
(1)

Includes stock-based compensation expense as follows (in thousands):

 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Cost of revenue

$

33,124

 

$

11,000

 

$

69,065

 

$

35,995

Sales and marketing

 

97,953

 

 

 

43,689

 

 

 

239,121

 

 

 

160,645

 

Research and development

 

77,533

 

 

 

32,996

 

 

 

165,065

 

 

 

98,064

 

General and administrative

 

73,188

 

 

 

44,923

 

 

 

218,387

 

 

 

181,199

 

Total stock-based compensation

$

281,798

 

 

$

132,608

 

 

$

691,638

 

 

$

475,903

 

 

Palantir Technologies Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

 

 

As of December 31,

 

 

2024

 

 

 

2023

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

2,098,524

 

 

$

831,047

 

Marketable securities

 

3,131,463

 

 

 

2,843,132

 

Accounts receivable, net

 

575,048

 

 

 

364,784

 

Prepaid expenses and other current assets

 

129,254

 

 

 

99,655

 

Total current assets

 

5,934,289

 

 

 

4,138,618

 

Property and equipment, net

 

39,638

 

 

 

47,758

 

Operating lease right-of-use assets

 

200,740

 

 

 

182,863

 

Other assets

 

166,217

 

 

 

153,186

 

Total assets

$

6,340,884

 

 

$

4,522,425

 

Liabilities and Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

103

 

 

$

12,122

 

Accrued liabilities

 

427,046

 

 

 

222,991

 

Deferred revenue

 

259,624

 

 

 

246,901

 

Customer deposits

 

265,252

 

 

 

209,828

 

Operating lease liabilities

 

43,993

 

 

 

54,176

 

Total current liabilities

 

996,018

 

 

 

746,018

 

Deferred revenue, noncurrent

 

39,885

 

 

 

28,047

 

Customer deposits, noncurrent

 

1,663

 

 

 

1,477

 

Operating lease liabilities, noncurrent

 

195,226

 

 

 

175,216

 

Other noncurrent liabilities

 

13,685

 

 

 

10,702

 

Total liabilities

 

1,246,477

 

 

 

961,460

 

Stockholders’ equity:

 

 

 

Common stock

 

2,339

 

 

 

2,200

 

Additional paid-in capital

 

10,193,970

 

 

 

9,122,173

 

Accumulated other comprehensive income (loss), net

 

(5,611

)

 

 

801

 

Accumulated deficit

 

(5,187,423

)

 

 

(5,649,613

)

Total stockholders’ equity

 

5,003,275

 

 

 

3,475,561

 

Noncontrolling interests

 

91,132

 

 

 

85,404

 

Total equity

 

5,094,407

 

 

 

3,560,965

 

Total liabilities and equity

$

6,340,884

 

 

$

4,522,425

 

 

Palantir Technologies Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

Years Ended December 31,

 

 

2024

 

 

 

2023

 

Operating activities

 

 

 

Net income

$

467,918

 

 

$

217,375

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

Depreciation and amortization

 

31,587

 

 

 

33,354

 

Stock-based compensation

 

691,638

 

 

 

475,903

 

Noncash operating lease expense

 

41,239

 

 

 

47,019

 

Unrealized and realized (gain) loss from marketable securities, net

 

19,306

 

 

 

13,160

 

Noncash consideration

 

(52,521

)

 

 

(46,609

)

Other operating activities

 

24,795

 

 

 

(34,255

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable, net

 

(211,157

)

 

 

(106,159

)

Prepaid expenses and other current assets

 

7,202

 

 

 

(6,197

)

Other assets

 

4,681

 

 

 

3,242

 

Accounts payable

 

(18,841

)

 

 

(31,832

)

Accrued liabilities

 

115,634

 

 

 

52,895

 

Deferred revenue, current and noncurrent

 

22,356

 

 

 

79,512

 

Customer deposits, current and noncurrent

 

54,440

 

 

 

64,347

 

Operating lease liabilities, current and noncurrent

 

(48,966

)

 

 

(49,630

)

Other noncurrent liabilities

 

4,554

 

 

 

58

 

Net cash provided by operating activities

 

1,153,865

 

 

 

712,183

 

Investing activities

 

 

 

Purchases of property and equipment

 

(12,634

)

 

 

(15,114

)

Purchases of marketable securities

 

(5,395,913

)

 

 

(5,636,406

)

Proceeds from sales and redemption of marketable securities

 

5,073,507

 

 

 

2,889,268

 

Other investing activities

 

(5,615

)

 

 

51,072

 

Net cash used in investing activities

 

(340,655

)

 

 

(2,711,180

)

Financing activities

 

 

 

Proceeds from the exercise of common stock options

 

745,396

 

 

 

218,238

 

Repurchases of common stock

 

(64,196

)

 

 

 

Taxes paid related to net share settlement of equity

 

(218,280

)

 

 

 

Other financing activities

 

444

 

 

 

601

 

Net cash provided by financing activities

 

463,364

 

 

 

218,839

 

Effect of foreign exchange on cash, cash equivalents, and restricted cash

 

(6,745

)

 

 

2,930

 

Net increase (decrease) in cash, cash equivalents, and restricted cash

 

1,269,829

 

 

 

(1,777,228

)

Cash, cash equivalents, and restricted cash – beginning of period

 

850,107

 

 

 

2,627,335

 

Cash, cash equivalents, and restricted cash – end of period

$

2,119,936

 

 

$

850,107

 

 

Palantir Technologies Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(unaudited)

 

Non-GAAP Reconciliations

Adjusted Income from Operations and Adjusted Operating Margin (in thousands, except percentages)

 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Income from operations

$

11,043

 

 

$

65,794

 

 

$

310,403

 

 

$

119,966

 

Add: stock-based compensation

 

281,798

 

 

 

132,608

 

 

 

691,638

 

 

 

475,903

 

Add: employer payroll taxes related to stock-based compensation

 

79,681

 

 

 

10,953

 

 

 

126,021

 

 

 

36,907

 

Adjusted income from operations

$

372,522

 

 

$

209,355

 

 

$

1,128,062

 

 

$

632,776

 

Adjusted operating margin

 

45

%

 

 

34

%

 

 

39

%

 

 

28

%

Income from Operations When Excluding One-Time SAR-Related Expenses and Operating Margin When Excluding One-Time SAR-Related Expenses (in thousands, except percentages
 

 

Three Months Ended

December 31, 2024

 

Years Ended

December 31, 2024

Income from operations

$

                      11,043

 

 

$

                    310,403

 

Add: accelerated stock-based compensation expense related to Market-Vesting SARs

 

                      115,776

 

 

 

                      115,776

 

Add: employer payroll taxes related to Market-Vesting SARs

 

                        15,528

 

 

 

                        15,528

 

Income from operations when excluding one-time SAR-related expenses

$

                    142,347

 

 

$

                    441,707

 

Operating margin when excluding one-time SAR-related expenses

 

17

%

 

 

15

%

Adjusted Free Cash Flow and Adjusted Free Cash Flow Margin (in thousands, except percentages)
 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net cash provided by operating activities

$

460,327

 

 

$

301,172

 

 

$

1,153,865

 

 

$

712,183

 

Add: cash paid for employer payroll taxes related to stock-based compensation

 

60,164

 

 

 

8,440

 

 

 

107,991

 

 

 

33,455

 

Less: purchases of property and equipment

 

(3,106

)

 

 

(4,860

)

 

 

(12,634

)

 

 

(15,114

)

Adjusted free cash flow

$

517,385

 

 

$

304,752

 

 

$

1,249,222

 

 

$

730,524

 

Adjusted free cash flow margin

 

63

%

 

 

50

%

 

 

44

%

 

 

33

%

Adjusted EBITDA and Adjusted EBITDA Margin (in thousands, except percentages)

 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net income attributable to common stockholders

$

79,009

 

 

$

93,391

 

 

$

462,190

 

 

$

209,825

 

Add: net income (loss) attributable to noncontrolling interests

 

(2,073

)

 

 

3,522

 

 

 

5,728

 

 

 

7,550

 

Less: interest income

 

(54,727

)

 

 

(44,545

)

 

 

(196,792

)

 

 

(132,572

)

Add: other (income) expense, net

 

(14,768

)

 

 

4,092

 

 

 

18,022

 

 

 

15,447

 

Add: provision for income taxes

 

3,602

 

 

 

9,334

 

 

 

21,255

 

 

 

19,716

 

Add: depreciation and amortization

 

7,006

 

 

 

7,972

 

 

 

31,587

 

 

 

33,354

 

Add: stock-based compensation

 

281,798

 

 

 

132,608

 

 

 

691,638

 

 

 

475,903

 

Add: employer payroll taxes related to stock-based compensation

 

79,681

 

 

 

10,953

 

 

 

126,021

 

 

 

36,907

 

Adjusted EBITDA

$

379,528

 

 

$

217,327

 

 

$

1,159,649

 

 

$

666,130

 

Adjusted EBITDA margin

 

46

%

 

 

36

%

 

 

40

%

 

 

30

%

Adjusted Net Income and Adjusted Earnings Per Share, Diluted (in thousands, except per share amounts and percentages)

 

 

Three Months Ended

December 31,

 

Years Ended

December 31,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net income attributable to common stockholders

$

79,009

 

 

$

93,391

 

 

$

462,190

 

 

$

209,825

 

Add: stock-based compensation

 

281,798

 

 

 

132,608

 

 

 

691,638

 

 

 

475,903

 

Add: employer payroll taxes related to stock-based compensation

 

79,681

 

 

 

10,953

 

 

 

126,021

 

 

 

36,907

 

Less: income tax effects and adjustments (1)

 

(98,541

)

 

 

(47,312

)

 

 

(278,000

)

 

 

(151,026

)

Adjusted net income attributable to common stockholders, diluted

$

341,947

 

 

$

189,640

 

 

$

1,001,849

 

 

$

571,609

 

Adjusted weighted-average shares used in computing adjusted earnings per share, diluted

 

2,528,279

 

 

 

2,357,741

 

 

 

2,450,818

 

 

 

2,297,928

 

Adjusted earnings per share, diluted

$

0.14

 

 

$

0.08

 

 

$

0.41

 

 

$

0.25

 

 

(1)

 

Income tax effect is based on long-term estimated annual effective tax rates of 23.0% for the periods ended 2024 and 2023.

Net Income When Excluding One-Time SAR-Related Expenses and Earnings Per Share When Excluding One-Time SAR-Related Expenses, Diluted (in thousands, except per share amounts and percentages)
 

 

Three Months Ended

December 31, 2024

Net income attributable to common stockholders

$

79,009

 

Add: accelerated stock-based compensation expense related to Market-Vesting SARs

 

115,776

 

Add: employer payroll taxes related to Market-Vesting SARs

 

15,528

 

Less: income tax effects and adjustments related to Market-Vesting SARs (1)

 

(45,599

)

Net income when excluding one-time SAR-related expenses

$

164,714

 

Net income when excluding one-time SAR-related expenses margin

20

%

Adjusted weighted-average shares used in computing earnings per share when excluding one-time SAR-related expenses, diluted

 

2,528,279

 

Earnings per share when excluding one-time SAR-related expenses, diluted

$

0.07

 

(1)

 

Income tax effect is based on long-term estimated annual effective tax rates of 23.0% for the period ended 2024.

 

Investor Relations

[email protected]

Media

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Software Other Defense Data Management White House/Federal Government Apps/Applications Technology Defense Artificial Intelligence Security Government Technology Military Public Policy/Government

MEDIA:

Logo
Logo